Enter Japan with Clarity.
Execute with Confidence

Providing end-to-end support
for emerging overseas
biopharmaceutical companies
seeking to enter
the Japanese market,
from market entry assessment
to regulatory
approval to
post-marketing
distribution.

Shigeki Ohashi

PATH-Solution is committed to helping improve access to innovative medicines in Japan by delivering them to patients as quickly as possible, safely and securely.
Through seamless, end-to-end support—from the early stage of considering entry into the Japanese market through commercialization—we work together with partners in Japan and overseas to contribute to addressing drug lag and loss and to advance the future of healthcare.

Shigeki Ohashi

Director, Vice President & Executive Officer

the Total Supply Chain Service (TSCS) ― 開発・製造・輸送・投薬の循環するサプライチェーン

Challenges to entering
the Japanese market

  • How complex
    are the
    regulatory
    requirements?

  • How will we
    build the
    right execution
    framework?

  • What level
    of investment
    will
    be
    required?

  • Which Japanese
    partners should
    we
    collaborate
    with?

Platform for
Accelerating Therapeutics in Healthcare

  • One unified platform supporting
    you from entry
    strategy to post-launch

  • Comprehensive market research,
    regulatory strategy,
    and premium distribution planning

  • Flexible,
    tailored entry models
    designed for each company

How PATH-Solution の支援内容: 上市前の参入検討から承認 / 上市後の流通 — 市場分析(参入可否判断支援)/開発(規制対応・開発支援)/製造(体制設計・製造支援)/販売・物流(流通支援)/PMS(PMS 支援)の各段階を The Alfresa Group and Its Alliance Partners が支援します
アルフレッサ ホールディングス PATH-Solution チーム メンバー

Enter Japan with Clarity.
Execute with Confidence

Let us meet at Bio !!